|Flexion Therapeutics Inc -- USA Stock|| |
USD 25.37 0.36 1.44%
Chief Medical Officer & Co-Founder
Dr. Neil Bodick, M.D., Ph.D. serves as Chief Scientific Officer of the Company. He was Chief Medical Officer of Flexion Therapeutics, Inc. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for earlyphase clinical investigation at Lilly Research Laboratories. He also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computerbased systems to support imageintensive diagnosis. Dr. Bodick holds 13 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health.
Age: 69 Founder Since 2017
Neil Bodick Latest Insider Activity
The company has return on total asset (ROA)
of (20.31) %
which means that it has lost $20.31 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (52.41) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 161.04 M in liabilities with Debt to Equity (D/E) ratio of 79.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Flexion Therapeutics Inc has Current Ratio of 17.92 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of antiinflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. Flexion Therapeutics Inc (FLXN) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 48 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.